Possible emergence of drug-resistant variants of Babesia gibsoni in clinical cases treated with atovaquone and azithromycin

Journal of Veterinary Internal Medicine

Volumn 23, Issue 3, 2009, Pages 493-498

  Sakuma, M ^a   Setoguchi, A ^a   Endo, Y ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Clinical pharmacology; Hematology; Nucleic acid sequencing; Therapeutics

Indexed keywords

ANTIPROTOZOAL AGENT; ATOVAQUONE; AZITHROMYCIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; BABESIA; BABESIOSIS; DOG; DOG DISEASE; DRUG EFFECT; DRUG RESISTANCE; FEMALE; MALE; PARASITOLOGY; RETROSPECTIVE STUDY;

ANIMALS; ANTIPROTOZOAL AGENTS; ATOVAQUONE; AZITHROMYCIN; BABESIA; BABESIOSIS; DOG DISEASES; DOGS; DRUG RESISTANCE; FEMALE; MALE; RETROSPECTIVE STUDIES;

AMBYSTOMA TIGRINUM STEBBENSI VIRUS; ANIMALIA; BABESIA; BABESIA GIBSONI; CANIS FAMILIARIS;

EID: 67449098413     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2009.0300.x     Document Type: Article

References (29)

1. Farwell GE, LeGrand EK, Cobb CC. Clinical observations on Babesia gibsoni and Babesia canis infection in dogs. J Am Vet Med Assoc 1982;180:507-511.
2. Boozer AL, Macintire DK. Canine babesiosis. Vet Clin North Am Small Anim Pract 2003;33:885-904.
3. Itoh N, Higuchi S, Kawamura S. The effect of diminazene aceturate on splenectomized dogs with Babesia gibsoni infection. Vet Clin Pathol 1988;17:94-98.
4. Wulansari R, Wijaya A, Ano H, et al. Lymphocyte subsets and specific IgG antibody levels in clindamycin-treated and untreated dogs experimentally infected with Babesia gibsoni. J Vet Med Sci 2003;65:579-584.
5. Suzuki K, Wakabayashi H, Takahashi M, et al. A possible treatment strategy and clinical factors to estimate the treatment response in Babesia gibsoni infection. J Vet Med Sci 2007;69:563-568.
6. Baggish AL, Hill DR. Antiparasitic agent atovaquone. Antimicrob Agents Chemother 2002;46:1163-1173.
7. Hughes WT, Oz H. Successful prevention and treatment of babesiosis with atovaquone. J Infect Dis 1995;172:1042-1046.
8. Pudney M, Gray JS. Therapeutic efficacy of atovaquone against the bovine intraerythrocytic parasites, Babesia divergens. J Parasitol 1997;83:307-310.
9. Gray J, Pudney M. Activity of atovaquone against Babesia microti in the Mongolian gerbil, Meriones unguiculatus. J Parasitol 1999;85:723-728.
10. Wittner M, Lederman J, Tanowitz HB, et al. Atovaquone in the treatment of Babesia microti infections in hamsters. Am J Trop Med Hyg 1996;55:219-222.
11. Weiss LM. Babesiosis in humans: A treatment review. Expert Opin Pharmacother 2002;3:1109-1115.
12. Srivastava IK, Morrisey JM, Darrouzet E, et al. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol Microbiol 1999;33:704-711.
13. Syafruddin D, Siregar JE, Marzuki S. Mutation in the cytochrome b gene of Plasmodium berghei conferring resistance to atovaquone. Mol Biochem Parasitol 1999;104:185-194.
14. Vaidya AB, Mather MW. Atovaquone resistance in malaria parasites. Drug Resist Updat 2000;3:283-287.
15. Korsinczky M, Chen N, Kotecka B, et al. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 2000;44:2100-2108.
16. McFadden DC, Tomavo S, Berry EA, et al. Characterization of cytochrome b from Toxoplasma gondii and Q domain mutations as a mechanism of atovaquone-resistance. Mol Biochem Parasitol 2000;108:1-12.
17. Hudson AT, Dickins MM, Ginger CD, et al. A broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp Clin Res 1991;17:427-435.
18. Shepard RM, Falkner FC. Pharmacokinetics of azithromycin in rats and dogs. J Antimicrob Chemother 1990;25:49-60.
19. Weiss LM, Wittner M, Wasserman S, et al. Efficacy of azithromycin for treating Babesia microti infection in the hamster model. J Infect Dis 1993;168:1289-1292.
20. Birkenheuer AJ, Levy MG, Breitschwerdt EB. Efficacy of combined atovaquone and azithromycin for therapy of chronic Babesia gibsoni (Asian genotype) infections in dogs. J Vet Intern Med 2004;18:494-498.
21. Jefferies R, Ryan UM, Jardine J, et al. Babesia gibsoni: Detection during experimental infections and after combined atovaquone and azithromycin therapy. Exp Parasitol 2007;117:115-123.
22. Matsuu A, Miyamoto K, Ikadai H, et al. Cloning of the Babesia gibsoni cytochrome b gene and isolation of three single nucleotide polymorphisms from parasites present after atovaquone treatment. Am J Trop Med Hyg 2006;74:593-597.
23. Birkenheuer AJ, Levy MG, Breitschwerdt EB. Development and evaluation of a seminested PCR for detection and differentiation of Babesia gibsoni (Asian genotype) and B. canis DNA in canine blood sample. J Clin Microbiol 2003;41:4172-4177.
24. Fukumoto S, Xuan X, Shigeno S, et al. Development of a polymerase chain reaction method for diagnosing Babesia gibsoni infection in dogs. J Vet Med Sci 2001;63:977-981.
25. Matsuu A, Koshida Y, Kawahara M, et al. Efficacy of atovaquone against Babesia gibsoni in vivo and in vivo. Vet Parasitol 2004;124:9-18.
26. Miyama T, Sakata Y, Shimada Y, et al. Epidemiological survey of Babesia gibsoni infection in dogs in eastern Japan. J Vet Med Sci 2005;67:467-471.
27. Verdida RA, Hara OA, Xuan X, et al. Serodiagnosis of Babesia gibsoni infection in dogs by an improved enzyme-linked immunosorbent assay with recombinant truncated P50. J Vet Med Sci 2004;66:1517-1521.
28. Jia H, Liao M, Lee E, et al. Development of an immunochromatographic test with recombinant BgSA1 for the diagnosis of Babesia gibsoni infection in dogs. Parasitol Res 2007;100: 1381-1384.
29. Matsuu A, Ono S, Ikadai H, et al. Development of a SYBR green real-time polymerase chain reaction assay for quantitative detection of Babesia gibsoni (Asian genotype) DNA. J Vet Diagn Invest 2005;17:569-573.